Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 852Neoplasms 643Prostatic Neoplasms 439Lung Neoplasms 359Colorectal Neoplasms 327Carcinoma, Non-Small-Cell Lung 318Leukemia, Myeloid, Acute 251Pancreatic Neoplasms 218Brain Neoplasms 202Multiple Myeloma 198Neoplasm Metastasis 191Carcinoma, Hepatocellular 178Head and Neck Neoplasms 176Glioblastoma 167Precursor Cell Lymphoblastic Leukemia-Lymphoma 166Melanoma 153Ovarian Neoplasms 149Squamous Cell Carcinoma of Head and Neck 148Rectal Neoplasms 134Recurrence 132Hematologic Neoplasms 125Sarcoma 124Uterine Cervical Neoplasms 117Stomach Neoplasms 116Carcinoma, Renal Cell 115Triple Negative Breast Neoplasms 114Glioma 114Motor Activity 100Myelodysplastic Syndromes 96Esophageal Neoplasms 96

Interventions

dehydroftorafur 1Taxes 1Radiotherapy 1Radiation 1Platinum 1Oxaliplatin 1Leucovorin 1Irinotecan 1Gemcitabine 1Fluorouracil 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Borderline Resectable Pancreatic Adenocarcinoma × 90 days × Clear all
NCT04481204 2026-05-04

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Borderline Resectable Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡